for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aptose Biosciences Inc

APTO.OQ

Latest Trade

2.42USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.58

 - 

3.13

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.42
Open
--
Volume
--
3M AVG Volume
5.22
Today's High
--
Today's Low
--
52 Week High
3.13
52 Week Low
1.58
Shares Out (MIL)
55.45
Market Cap (MIL)
131.12
Forward P/E
-4.41
Dividend (Yield %)
--

Latest Developments

More

Aptose Biosciences Reports Qtrly Loss Per Share $0.12

Aptose Biosciences Reports Qtrly Net Loss Per Share Of $0.13

Aptose Announces Pricing Of Public Offering Of Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aptose Biosciences Inc

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Industry

Biotechnology & Drugs

Contact Info

251 Consumers Rd Suite 1105

+1.647.4799828

https://aptose.com/

Executive Leadership

William Glenn Rice

Chairman of the Board, President, Chief Executive Officer

Gregory Kwok Lee Chow

Chief Financial Officer, Senior Vice President

Jotin Marango

Senior Vice President, Chief Business Officer

Carol Gail Ashe

Director

Caroline M. Loewy

Director

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.087

2017

-0.520

2018

-0.860

2019(E)

-0.539
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.97
LT Debt To Equity (MRQ)
4.10
Return on Investment (TTM)
-116.92
Return on Equity (TTM)
-101.86

Latest News

Latest News

BRIEF-Aptose Biosciences Says Exercises Early Option For Cg-806 License From Crystalgenomics

* APTOSE BIOSCIENCES INC - EXERCISES EARLY OPTION FOR CG-806 LICENSE FROM CRYSTALGENOMICS

BRIEF-Aptose Biosciences Establishes New At-The-Market Facility

* APTOSE BIOSCIENCES INC SAYS ENTERED INTO AN "AT-THE-MARKET" SALES AGREEMENT WITH CANTOR FITZGERALD & CO

BRIEF-Aptose Reports Qtrly Loss Of $0.12 Per Share

* APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology

* APTOSE BIOSCIENCES - AGREEMENT PROVIDES OHM ONCOLOGY RIGHTS FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF APL-581

BRIEF-Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 Mln

* APTOSE BIOSCIENCES INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING Source text : http://bit.ly/2BJGvqH Further company coverage:

BRIEF-FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia

* FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

BRIEF-Aptose Biosciences Inc Q3 loss per share C$0.14

* Aptose reports results for the third quarter ended September 30, 2017

BRIEF-Aptose enters into $15.5 mln common shares purchase agreement with Aspire Capital Fund, Llc

* Aptose enters into $15.5 million common shares purchase agreement with Aspire Capital Fund, Llc

BRIEF-Aptose Biosciences Inc qtrly earnings per share $0.15

* Aptose reports results for the second quarter ended June 30, 2017

BRIEF-Aptose Q1 loss per share C$0.25

* Aptose reports results for the first quarter ended March 31, 2017

BRIEF-Aptose reports Q4 and year end 2016 results

* Q4 loss per share c$0.26 Source text for Eikon: Further company coverage:

BRIEF-Aptose prioritizes development of CG'806 first-in class FLT3/BTK Inhibitor

* Will prioritize resources toward development of CG'806 for patients with FLT3-driven acute myeloid leukemia (AML)

BRIEF-Aptose Biosciences Q3 shr loss $0.31

* Aptose Biosciences reports financial results for the third quarter ended september 30, 2016 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up